Richard Bernstein Advisors LLC Cuts Stock Holdings in AbbVie Inc. $ABBV

Richard Bernstein Advisors LLC lessened its position in AbbVie Inc. (NYSE:ABBV) by 59.1% during the third quarter, Holdings Channel.com reports. The fund owned 13,362 shares of the company’s stock after selling 19,310 shares during the period. Richard Bernstein Advisors LLC’s holdings in AbbVie were worth $3,094,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. Brighton Jones LLC boosted its stake in AbbVie by 17.4% in the fourth quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock worth $4,072,000 after purchasing an additional 3,401 shares in the last quarter. Revolve Wealth Partners LLC lifted its holdings in shares of AbbVie by 72.7% during the 4th quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock worth $1,294,000 after acquiring an additional 3,064 shares during the last quarter. Schnieders Capital Management LLC. raised its stake in shares of AbbVie by 5.0% in the second quarter. Schnieders Capital Management LLC. now owns 16,466 shares of the company’s stock worth $3,056,000 after purchasing an additional 789 shares during the last quarter. Penserra Capital Management LLC grew its stake in AbbVie by 500.0% during the second quarter. Penserra Capital Management LLC now owns 864 shares of the company’s stock valued at $159,000 after acquiring an additional 720 shares in the last quarter. Finally, Fox Run Management L.L.C. purchased a new position in AbbVie during the 2nd quarter worth $581,000. 70.23% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, EVP Perry C. Siatis sold 22,381 shares of the business’s stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the transaction, the executive vice president directly owned 38,137 shares in the company, valued at $8,771,510. The trade was a 36.98% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP David Ryan Purdue sold 5,230 shares of the stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total value of $1,221,518.80. Following the sale, the senior vice president owned 2,654 shares in the company, valued at approximately $619,868.24. This represents a 66.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.08% of the stock is currently owned by insiders.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Phase 1 ABBV‑295 (long‑acting amylin analog) topline results showed clinically meaningful weight loss (~7.8%–9.8% at ~12–13 weeks) with a favorable tolerability profile, supporting continued development of a non‑incretin obesity treatment — a potential new growth driver outside AbbVie’s GI/immunology franchise. AbbVie Announces Positive Topline Results from a Phase 1 Multiple Ascending Dose Study of ABBV-295, a Long-Acting Amylin Analog, in Adults
• Positive Sentiment: Positive topline Phase 3 AFFIRM results for SKYRIZI (risankizumab) in Crohn’s disease increase the likelihood of label expansion and incremental revenue from AbbVie’s immunology franchise. This helps the company’s growth outlook beyond its legacy products. AbbVie Inc. (ABBV) Announces Positive Topline Results from Phase 3 AFFIRM Study Evaluating SKYRIZI Subcutaneous Induction in Patients with Crohn’s Disease
• Positive Sentiment: Major broker support remains — J.P. Morgan has stuck with a buy rating, which can help stabilize sentiment amid pipeline news and support investor demand. J.P. Morgan Sticks to Its Buy Rating for AbbVie (ABBV)
• Neutral Sentiment: Analyst and retail attention is rising (momentum screens and coverage), which can amplify moves but doesn’t guarantee directional conviction; investors should watch follow‑on data and commercialization signals. Here’s Why AbbVie (ABBV) is a Strong Momentum Stock
• Neutral Sentiment: Recent trial updates (Crohn’s + ABBV‑295) are being used to re‑price AbbVie’s mid‑term valuation; they add context but require regulatory, commercial and longer‑term outcome confirmation. AbbVie Trial Updates Add Context To Valuation And Growth Outlook
• Negative Sentiment: ICER will review AbbVie’s Parkinson’s disease drug, introducing potential pricing and reimbursement scrutiny that could limit commercial upside or pressure expected margins for that program. ICER to review AbbVie’s Parkinson’s disease drug
• Negative Sentiment: Market reaction has been mixed — reports note shares fell after the early obesity data, suggesting investors may be taking profits or weighing valuation against what remains early‑stage evidence. AbbVie’s Early Obesity Drug Data Shows Up To 10% Weight Loss
• Negative Sentiment: An AbbVie SVP sold about $1.22M of stock; insider sales can be read as a near‑term negative signal even if not uncommon at large companies. AbbVie (NYSE:ABBV) SVP Sells $1,221,518.80 in Stock

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on ABBV shares. Morgan Stanley increased their target price on AbbVie from $269.00 to $270.00 and gave the company an “overweight” rating in a report on Thursday, February 5th. The Goldman Sachs Group restated a “neutral” rating and set a $223.00 price objective on shares of AbbVie in a research report on Wednesday, January 28th. Piper Sandler upped their price objective on AbbVie from $289.00 to $299.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 18th. BMO Capital Markets restated an “outperform” rating on shares of AbbVie in a research report on Monday. Finally, Barclays assumed coverage on shares of AbbVie in a report on Thursday, February 19th. They set an “overweight” rating and a $275.00 price target on the stock. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $253.15.

AbbVie Stock Down 1.0%

Shares of NYSE:ABBV opened at $227.75 on Tuesday. The firm’s 50 day moving average price is $224.66 and its 200 day moving average price is $224.33. AbbVie Inc. has a fifty-two week low of $164.39 and a fifty-two week high of $244.81. The stock has a market cap of $402.70 billion, a price-to-earnings ratio of 96.50, a price-to-earnings-growth ratio of 0.80 and a beta of 0.34.

AbbVie (NYSE:ABBV) last posted its earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, topping analysts’ consensus estimates of $2.65 by $0.06. The business had revenue of $16.62 billion for the quarter, compared to analyst estimates of $16.39 billion. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The firm’s revenue was up 10.0% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.16 EPS. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, equities analysts anticipate that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be issued a dividend of $1.73 per share. The ex-dividend date is Wednesday, April 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.0%. AbbVie’s dividend payout ratio is presently 293.22%.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.